Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 94, Issue 5, Pages 562-565Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2013.164
Keywords
-
Categories
Funding
- National Institute of General Medical Sciences [R24 GM078233]
- American Recovery and Reinvestment Act [U01 HL069757]
Ask authors/readers for more resources
Statins reduce risk of cardiovascular disease (CVD) by decreasing plasma low-density lipoprotein (LDL) concentrations, as well as reducing inflammation and improving endothelial function. Despite their documented efficacy, there is considerable interindividual variation in effects of statins on CVD biomarkers. In the studies summarized here, we used complementary metabolomics platforms to define global effects of a statin (simvastatin) on metabolism and to identify markers indicative of mechanisms that contribute to variation in plasma LDL response to statin treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available